Skip to content

Predictors of Clinical Course and Treatment Response in DBT Programmes

Predictors of Clinical Course and Treatment Response in Patients Having Received Dialectical Behaviour Therapy Delivered by Clinical Units in the Norwegian Network for Clinical Evaluation and Quality in DBT Programmes

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04318899
Enrollment
250
Registered
2020-03-24
Start date
2018-01-01
Completion date
2025-12-31
Last updated
2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline Personality Disorder, Self Harm

Keywords

self harm, dialectical behaviour therapy, borderline personality disorder, emotional dysregulation

Brief summary

The project is a collaboration between The National Centre for Suicide Research and Prevention (NSSF) and clinical units with Dialectical Behaviour Therapy (DBT) programmes. A methodological and technological platform has been established that enables clinicians to deliver high quality treatments over extended periods of time, to evaluate their own performance and productivity and to report it in a uniform and systematic way that will enable comparison across clinical settings and programmes. The collected data constitute the basis for conducting the clinical study with the overall aim to study predictors of the clinical course and treatment response in patients admitted to DBT programmes in Norway.

Detailed description

The aim of the project is to collect data from systematic and uniform clinical assessments to study predictors of the clinical course and treatment response in patients admitted to and treated in clinical units delivering Dialectical Behaviour Therapy in Norway. Aims and research questions: The study will address the following main research questions: 1. Which patient characteristics (sociodemographic variables, psychiatric diagnoses/comorbidities, previous suicidal and self-harming behaviour, previous treatment history), predict a favourable clinical course and treatment response? 2. Which factors mediate the clinical change in key outcomes such as a) target symptom levels (depression, hopelessness, suicidal ideation, borderline symptoms etc.), b) function levels (emotion regulation capacity, use of coping skills, social functioning, occupational / academic performance level etc.), c) problem behaviours (suicide attempts, non-suicidal self-harm, substance abuse, eating disorder symptoms etc.), d) global functioning and e) the use of emergency treatment services. 3. What are significant moderators of treatment response with respect to key clinical outcomes (mentioned above)? 4. Which of the treatment modalities are evaluated as the most salient and helpful by patients who receive the treatment according to their age, gender, psychiatric diagnoses and previous treatment history? Methods: A uniform protocol for psychiatric diagnostics and clinical assessment of patients who receive treatment at the participating clinical units will be used. Since some participating clinical units will treat adult patients and some will treat children and adolescents, the protocol will offer assessment instrument suitable for the specific age group whenever this is relevant. The evaluation system includes assessments at baseline before treatment starts, evaluation at several time points during the treatment period, at termination of treatment and at follow-up. Assessments will be made both through interviews and ratings made by therapists and through self-report from patients. Self-reports will be filled out electronically by patients, on tablets stationed at each participating clinical unit. At intervals patients will also provide self-rated information on dimensions such as emotions, cognitions and impulsive behaviour several times per day through a mobile app developed specifically for the purpose, so-called Ecological Momentary Assessment (EMA). Interview data and ratings will be entered into the database by each clinician to tablets in a similar fashion as self-report data from patients.

Interventions

BEHAVIORALDialectical Behaviour Therapy adapted for adolescents (DBT-A)

DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus & Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.

BEHAVIORALDialectical Behaviour Therapy - Standard version (DBT)

DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.

Sponsors

Vestre Viken Hospital Trust
CollaboratorOTHER
St. Olavs Hospital
CollaboratorOTHER
Sykehuset Ostfold
CollaboratorOTHER
University of Oslo
CollaboratorOTHER
Nordlandssykehuset HF
CollaboratorOTHER
Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* History of repeated deliberate self harm * Satisfies criteria of Diagnostic and Statistical Manual (DSM-IV) Borderline Personality Disorder as measured by Structured Clinical Interview for the DSM (SCID-II) in addition to the self-destructive criterion.

Exclusion criteria

* Psychotic disorders * Anorexia Nervosa * Substance dependence disorder * Mental retardation (IQ less than 70) * Asperger syndrome/autism

Design outcomes

Primary

MeasureTime frameDescription
Depressive symptoms (adults)1 weekBeck Depression Inventory (BDI). Min=0, Max=63. Higher scores indicate worse outcome
Suicidal Ideation (adults)4 weeksBeck Scale for Suicidal Ideation (BSS). MIn=0, Max=38. Higher scores indicate worse outcome
Depressive symptoms (adolescents)1 weekMoods and Feelings Questionnaire (MFQ). Min=0, Max=26. Higher scores indicate worse outcome
Self-harm behaviour4 weeksNumber of self-harm episodes (split on suicide attempts and non-suicidal self-harm)
Suicidal Ideation (adolescents)2 weeksSuicidal Ideation Questionnaire (SIQ-Jr). Min=0, Max=90. Higher scores indicate worse outcome
Depressive symptoms1 weekMADRS (Montgomery Asberg Depression Rating Scale).Min=0, Max=60. Higher scores indicate worse outcome

Secondary

MeasureTime frameDescription
Hopelessness1 weekBeck Hopelessness Scale (BHS). Min=0, Max=20. Higher scores indicate more hopelessness.
Borderline Symptoms1 weekBorderline Symptom List (BSL-23). Min=0, Max=92. Higher scores indicate more symptoms.

Countries

Norway

Contacts

Primary ContactEgil Haga, PhD
egil.haga@medisin.uio.no+4722923442
Backup ContactLars Mehlum, MD PhD
lars.mehlum@medisin.uio.no+4722923442

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026